Isoniazid News and Research

RSS

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Eating food just before taking TB drug could reduce effectiveness of medicine

The timing of food intake in the early phase of TB treatment could have a negative impact on the effectiveness of TB treatment.

8 Sep 2014

Tuberculosis in children: an interview with Dr Peter Dodd, University of Sheffield

It was recently announced that new estimates indicated over 650,000 children develop tuberculosis (TB) every year in the 22 countries with a high burden of the disease (HBCs). Which countries are these and why are so many children developing TB in these areas?

29 Jul 2014

Over 650 000 children develop tuberculosis every year in the 22 HBCs according to new estimates

New estimates indicate that over 650 000 children develop tuberculosis (TB) every year in the 22 countries with a high burden of the disease (HBCs)*—almost 25% higher than the total number of new cases worldwide estimated by WHO in 2012 (530 000)**. The research, published in The Lancet Global Health, also suggests that about 15 million children are exposed to TB every year, and roughly 53 million are living with latent TB infection, which can progress to infectious active TB at any time.

9 Jul 2014

Otsuka's Deltyba gets EC marketing authorization for MDR-TB treatment

Otsuka Pharmaceutical Co., Ltd. today announced that the European Commission has granted a marketing authorization for Deltyba (delamanid) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

30 Apr 2014

TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

In an effort to develop and deliver treatments for children with tuberculosis—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments.

30 Oct 2013

Three rapid diagnostic tests could be used to diagnose drug resistance in TB

Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.

10 Sep 2013

BP and headache drug effectively speeds up treatment of TB

Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily antibiotic regimen. Test animals were cured in four months instead of the usual six.

30 Aug 2013

Preventive antibiotics for HIV patients lower risk of TB or death

As part of the largest international research effort ever made to combat tuberculosis, a team of Johns Hopkins and Brazilian experts has found that preventive antibiotic therapy for people with HIV lowers this group's chances of developing TB or dying.

16 Aug 2013

Scientists discover new drug that cripples TB bug by dissolving its protective fatty coating

Most humans would like to shed their fatty exteriors, but tuberculosis (TB)-causing bacteria rely on theirs for survival. Scientists at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School have now discovered a drug that cripples the TB bug by dissolving its protective fatty coating, a finding that could eventually be used to improve TB treatment in humans. The study has been posted online by Nature Chemical Biology.

19 Jun 2013

Scientists discover new anti-tuberculosis compound that kills drug-resistant TB bacteria

An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.

18 Jun 2013

TSRI scientists identify highly promising new anti-tuberculosis compound

An international team led by scientists at The Scripps Research Institute, the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis bacterium in two different ways.

18 Jun 2013

Viewpoints: Scalia's 'boost' to Obamacare; California small biz and insurance exchange; Health law's hidden tax

[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.

1 Jun 2013

Vitamin C kills drug-resistant TB bacteria in lab

In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis bacteria in laboratory culture.

22 May 2013

Improving tuberculosis (TB) diagnosis: an interview with Professor Madhukar Pai, MD, PhD

TB is an infectious disease caused by Mycobacterium tuberculosis. Nearly 9 million people develop TB every year, and TB kills nearly 1.4 million individuals each year. While the incidence of TB has steadily declined in the west, it remains a huge public health problem in many developing countries, with India having the highest burden.

15 Feb 2013

TB test offers rapid detection of TB and drug-resistant strains according to new study

A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem.

31 Jan 2013

Researchers uncover new way that some bacteria survive when under siege by antibiotics

Researchers have uncovered a new way that some bacteria survive when under siege by antibiotics.

4 Jan 2013

Infectex initiates enrollment in SQ109 Phase IIb-III trial for MDR-TB

Infectex, a Russian biotech company in Maxwell Biotech Venture Fund's portfolio, announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize innovative products for the treatment of TB.

19 Dec 2012

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

12 Dec 2012

Natural antibiotic to treat tuberculosis

A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, works.

17 Sep 2012